MCM, LabCorp clinical trials enter master service agreement

LabCorp chief medical officer Dr Mark Brecher said, "MCM is a leading diagnostic laboratory and central lab in Japan with considerable experience and long-standing relationships in the medical and pharmaceutical communities."

Built on the strengths and capabilities of both companies, the agreement enables LabCorp Clinical Trials and MCM to expand their service offerings in Japan and across the globe.

MCM president and CEO Shinichi Yoshihara said that pharmaceutical sponsors continue to look to new markets and technologies for drug development opportunities.

"We are therefore excited to work closely with LabCorp as a global leader in central lab, biomarker and specialty testing, and with cutting-edge technologies from both sides we are confident this partnership will provide new channels of growth and competitive advantage for both companies," Yoshihara added.